LXRX Lexicon Pharmaceuticals, Inc.
XNAS
1.85
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
LXRX
$1.85
—
What changed
Recent filings, trades and movesKey stats
$1.85
- 52-Week Range
- $1.10 – $2.68
- YTD
- +62.25%
- Straddle Price
- $0.53
- P/C Vol Ratio
- 0.55
- Market Cap
- $0.8B
- Open
- $1.88
- Day Range
- $1.83 – $1.92
- Volume
- 1,567,175
- Prev Close
- $1.78
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.90% |
| Beta vs SPY | 1.51 |
| Cost of Equity (CAPM) | 13.19% (VRP-adj) |
| WACC | 12.77% |
| Volatility Risk Premium | +135.4pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -35.0% |
| Book / Price | 20.7% |
| Gross Margin (TTM) | 98.9% |
| FCF Margin (TTM) | -169.3% |
| Debt / Equity | 0.32 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $1.81 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $1.54 |
| Bollinger Width / SMA20 | 23.8% (drives anchor stability) |
| Net Debt | $0.0B |
| Market Cap | $1B |
Peers used for multiples: LLY, MANE, MAZE, PCRX, SEPN, SUPN, VTRS, XERS
60-Day Conviction
88%
20-Day Fair Value
≈ by Dec 8, 2026
$1.85
α -0.5%
rank 28%
conviction
39%
40-Day Fair Value
≈ by Jan 6, 2027
$1.95
α +4.4%
rank 38%
conviction
93%
60-Day Fair Value
≈ by Feb 4, 2027
$1.96
α +4.8%
rank 40%
conviction
88%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 15.2× · 5 peers |
| Peer P/B | $1.13 | 16% | median 3.1× · 6 peers |
| Peer P/S | $0.61 | 16% | median 7.1× · 7 peers |
| Market Anchor (SMA50) | $1.81 | 68% | stability 82% (BB-width) |
| Options Expected (B-L 30d) | n/a | 0% |
As of 2026-11-09 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $0.8B
- Employees
- 81
- List Date
- 2000-04-07
- CIK
- 0001062822
- Last Earnings
- Nov 5 before open · +8.8% vs ±49.0% expected
- Next Earnings
- ~Jan 28, 2027 (estimated)
- Headquarters
- The Woodlands, TX
- Homepage
- https://www.lexpharma.com
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 124.72% | -18.51% | 12.56% | 17.61% | -2.69% | 1.75% | 22.57% |
| Feb | -13.06% | -36.89% | -0.88% | 25.76% | -3.84% | 17.60% | -1.88% |
| Mar | -22.76% | -0.95% | 10.45% | -3.23% | 57.48% | 0.00% | 6.83% |
| Apr | -17.21% | -19.56% | -2.85% | -32.46% | 57.47% | -1.83% | -2.74% |
| May | -9.30% | -8.29% | 35.25% | 3.03% | -13.51% | 33.74% | 6.82% |
| Jun | 2.68% | 6.29% | -15.50% | -4.00% | 52.14% | 15.94% | 9.59% |
| Jul | -18.81% | 22.68% | -13.36% | 34.33% | 21.03% | -2.74% | 7.19% |
| Aug | 29.32% | 16.03% | -11.34% | -14.36% | 2.80% | -3.43% | 3.17% |
| Sep | 1.91% | -13.04% | -35.50% | -2.48% | 20.54% | -14.38% | -7.16% |
| Oct | 9.75% | -12.24% | 21.57% | 23.42% | -2.13% | -21.98% | 3.06% |
| Nov | -19.37% | -3.60% | -20.90% | -34.12% | 5.15% | 28.82%* | -7.34% |
| Dec | -13.97% | -10.75% | 33.04% | -7.79% | -15.44% | -- | -2.98% |
| Total | -5.22% | -62.67% | -13.28% | -19.58% | 298.50% | 47.22% | 40.83% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $1.55
SMA 50: $1.80
SMA 200: $1.89
Current: $1.86
EMA 12: $1.60
EMA 26: $1.64
MACD: -0.0356 | Signal: 0.0576
BEARISH
ADX (14): 36.87
TREND
+DI: 33.96
−DI: 17.47
Momentum Oscillators
RSI (14): 65.41
NEUTRAL
Stoch %K: 88.98
Stoch %D: 70.64
Williams %R: -9.55
Volume & Volatility
BB Upper: $1.77
BB Lower: $1.32
OVERBOUGHT
OBV: 400,020,726
Vol SMA 20: 1,990,983
Vol ROC: -29.09%
ATR: $0.11
True Range: $0.14
HV 20: 68.5%
HV 30: 60.2%
HV 60: 60.5%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-11-08T00:00:00 – 2026-11-06T00:00:00
AI Analysis
Click Frenzy-Pro™ for an AI analysis of this ticker.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
News
All LXRX news →
Novo Nordisk milestone payment shapes quarter as HCM readout nears.
Earnings History
18 of 21 under expected move
Avg Expected Move
22.58%
Avg Actual Move
9.37%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-03-10 | After-Close | 18.08% | 4.79% | 0.26x | Within |
| 2021-05-06 | After-Close | 8.97% | 2.69% | 0.30x | Within |
| 2021-07-30 | After-Close | 18.36% | 3.11% | 0.17x | Within |
| 2021-11-03 | After-Close | 11.09% | 13.86% | 1.25x | Exceeded |
| 2022-02-28 | After-Close | 21.26% | 1.93% | 0.09x | Within |
| 2022-08-02 | After-Close | 30.77% | 3.46% | 0.11x | Within |
| 2022-11-09 | After-Close | 16.33% | 14.29% | 0.88x | Within |
| 2023-03-02 | After-Close | 14.22% | 22.94% | 1.61x | Exceeded |
| 2023-05-02 | After-Close | 25.63% | 15.13% | 0.59x | Within |
| 2023-08-03 | After-Close | 16.15% | 2.60% | 0.16x | Within |
| 2024-03-11 | After-Close | 15.30% | 10.32% | 0.67x | Within |
| 2024-05-02 | After-Close | 15.88% | 2.35% | 0.15x | Within |
| 2024-08-01 | Pre-Market | 18.89% | 10.22% | 0.54x | Within |
| 2024-11-12 | Pre-Market | 39.37% | 6.30% | 0.16x | Within |
| 2025-05-13 | After-Close | 31.75% | 15.57% | 0.49x | Within |
| 2025-08-06 | After-Close | 17.39% | 2.61% | 0.15x | Within |
| 2025-11-06 | After-Close | 33.22% | 12.59% | 0.38x | Within |
| 2026-01-29 | After-Close | 34.72% | 19.44% | 0.56x | Within |
| 2026-05-07 | After-Close | 13.39% | 19.05% | 1.42x | Exceeded |
| 2026-08-06 | After-Close | 24.36% | 4.66% | 0.19x | Within |
| 2026-11-05 | Pre-Market | 48.99% | 8.78% | 0.18x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
LXRX Options Activity & IV Rank
Volatility Metrics
Current IV: —
7-DTE IV: —
Expected Move: $0.53
7-DTE Move: $0.48
Days to Exp: 39 (2026-12-18)
Options Flow · All expiries
Call Volume: 1,180
Put Volume: 644
P/C Volume: 0.546
BULLISH
Call OI: 25,655
Put OI: 1,666
P/C OI: 0.065
Total OI: 27,321
ATM Options Pricing
ATM Call: $0.20
ATM Put: $0.33
Call %: 10.8%
Put %: 17.6%
Chain Summary
Chain Volume: 1,824
Chain OI: 27,321
Last Updated: 11/9/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 34th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
34%
vs own history
GEX tilt
+0.33
OI-weighted, today
Vanna tilt
+0.39
δ-sensitivity to IV
Charm tilt
-0.15
δ-decay vs time
Vanna tilt +0.39: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
? What is this?
· 6 ATM contracts, 2k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.53Nov 9
Beta Analysis
Risk Metrics
Beta: 1.1344
Alpha: 52.31%
Correlation: 0.2110
R-Squared: 4.5%
Stock Volatility: 74.1%
Market Volatility: 13.8%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Above average volatility - stock moves with market amplification
Above average volatility - stock moves with market amplification
Beta & Alpha Over Time
Notable investors who own LXRX
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $19.8M | #588 of 1945 | +5.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $3.8M | #2301 of 6285 | +46.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $2.7M | #2407 of 3716 | -77.1% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $2.7M | #1802 of 3138 | -29.6% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $1K | #4559 of 4729 | -10.4% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
LXRX Institutional Ownership (13F)
Filings for 2026-06-30 · 52 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 411,504,750 (as of 2026-09-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$5.09M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.60M | 31.52% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $1.40M | 27.48% | 2026-06-30 |
| 3 | GROUP ONE TRADING LLC Custodian | $1.11M | 21.75% | 2026-06-30 |
| 4 | Citadel Advisors LLC Custodian | $886.32K | 17.41% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $93.56K | 1.84% | 2026-09-30 |
4 filers$162.16K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | GROUP ONE TRADING LLC Custodian | $51.12K | 31.52% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $42.96K | 26.49% | 2026-06-30 |
| 3 | Susquehanna International Group, LLP Custodian | $42.96K | 26.49% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $25.12K | 15.49% | 2026-09-30 |
LXRX Insider Trading (Form 4)
Latest: 2026-06-04Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Christopher J Sobecki | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-06-04 | Ivan Cheung | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-06-04 | Raymond Debbane | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-06-04 | Philippe Amouyal | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-06-04 | Judith L Swain | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-06-04 | Diane E. Sullivan | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-06-04 | Sam L Barker | Director | Exer (M) | +89,312 | — | EDGAR | |
| 2026-05-08 | International S.C.A. Artal | Director | Exer (M) | +20,421,735 | — | EDGAR | |
| 2026-05-04 | Ivan Cheung | Director | Grant (A) | +79,192 RSU | — | EDGAR | |
| 2026-05-04 | Sam L Barker | Director | Grant (A) | +79,192 opt | — | EDGAR | |
| 2026-05-04 | Philippe Amouyal | Director | Grant (A) | +79,192 RSU | — | EDGAR | |
| 2026-05-04 | Raymond Debbane | Director | Grant (A) | +79,192 RSU | — | EDGAR | |
| 2026-05-04 | Christopher J Sobecki | Director | Grant (A) | +79,192 RSU | — | EDGAR | |
| 2026-05-04 | Judith L Swain | Director | Grant (A) | +79,192 opt | — | EDGAR | |
| 2026-05-04 | Diane E. Sullivan | Director | Grant (A) | +79,192 RSU | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
LXRX Insider Holdings
19 insiders · @ $1.86
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | International S.C.A. Artal | Director | 175,156,062 | $326.67M | $6.75M | 2 | 2026-05-08 |
| 2 | Raymond Debbane | Director | 3,533,960 | $6.59M | $5.17M | 35 | 2026-06-04 |
| 3 | Michael Exton | Chief Executive Officer | 503,263 | $938.6K | $0 | 4 | 2026-03-03 |
| 4 | Brian T Crum | SVP, General Counsel & Secr. | 428,802 | $799.7K | $0 | 15 | 2026-03-03 |
| 5 | Artal Group S.A. | Director | 408,434 | $761.7K | $42.43M | 3 | 2026-02-19 |
| 6 | Philippe Amouyal | Director | 374,486 | $698.4K | $201.5K | 26 | 2026-06-04 |
| 7 | Christopher J Sobecki | Director | 293,177 | $546.8K | $302.5K | 27 | 2026-06-04 |
| 8 | Alan J Main | EVP, Innov & Chem Sciences | 281,391 | $524.8K | $0 | 36 | 2025-03-03 |
| 9 | Sam L Barker | Director | 218,771 | $408.0K | $148.9K | 30 | 2026-06-04 |
| 10 | Wendy McDermott | SVP, Human Resources | 201,659 | $376.1K | $35.3K | 12 | 2026-03-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
LXRX Board & Officers
As of SEC filings through Jun 4, 2026Directors 19
- Sam L Barker · on file since 2006
- Christopher J Sobecki · since Aug 28, 2007
- Philippe Amouyal · since Aug 28, 2007
- Judith L Swain · since Sep 24, 2007
- Raymond Debbane · listed since May 2010
- Administratiekantoor Westend Stichting · since Mar 31, 2012
- Artal Group S.A. (entity) · since Mar 31, 2012
- Artal International Management S.A. (entity) · since Mar 31, 2012
- International S.C.A. Artal · since Mar 31, 2012
- Westend S.A. (entity) · since Mar 31, 2012
- Amaury Wittouck · since Jan 11, 2021
- Diane E. Sullivan · since Jul 27, 2023
- Michael Exton · since Jul 8, 2024
- Invus Global Management, LLC (entity) · since Jul 25, 2024
- Siren, L.L.C. (entity) · since Jul 25, 2024
- Ivan Cheung · since Dec 2, 2024
- Artal Participations S.a r.l. (entity) · since Dec 5, 2024
- Avicenna Life Sci Master Fund LP (entity) · since Feb 2, 2026
- Avicenna Life Sci Master GP LLC (entity) · since Feb 2, 2026
Officers 8
- Michael Exton · Chief Executive Officer · since Jul 8, 2024
- Scott M Coiante · SVP, Chief Financial Officer · since Jan 2, 2025
- Craig B Granowitz · SVP, Chief Medical Officer · since Aug 2, 2021
- Brian T Crum · SVP, General Counsel & Secr. · listed since Feb 2022
- Wendy McDermott · SVP, Human Resources · listed since Feb 2025
- Lisa DeFrancesco · SVP, IR and Corp Comm · listed since Mar 2025
- Suma Gopinathan · SVP, Discovery · since Jun 1, 2025
- Rachel Yap Martens · SVP, Partnerships & Corp Strat · listed since Feb 2026
10% owners 11
- Administratiekantoor Westend Stichting · since Mar 31, 2012
- Amaury Wittouck · since Jan 11, 2021
- Artal Group S.A. (entity) · since Mar 31, 2012
- Artal International Management S.A. (entity) · since Mar 31, 2012
- Artal Participations S.a r.l. (entity) · since Dec 5, 2024
- Avicenna Life Sci Master Fund LP (entity) · since Feb 2, 2026
- Avicenna Life Sci Master GP LLC (entity) · since Feb 2, 2026
- International S.C.A. Artal · since Mar 31, 2012
- Invus Global Management, LLC (entity) · since Jul 25, 2024
- Siren, L.L.C. (entity) · since Jul 25, 2024
- Westend S.A. (entity) · since Mar 31, 2012
Changes in the last 10 years (50)
| Feb 17, 2026 | Rachel Yap Martens listed as SVP, Partnerships & Corp Strat (previously VP, Partnerships & Corp Strat) in SEC filings |
| Feb 2, 2026 | Avicenna Life Sci Master GP LLC became a director |
| Feb 2, 2026 | Avicenna Life Sci Master GP LLC became a 10% owner |
| Feb 2, 2026 | Avicenna Life Sci Master Fund LP became a director |
| Feb 2, 2026 | Avicenna Life Sci Master Fund LP became a 10% owner |
| Jun 1, 2025 | Suma Gopinathan became SVP, Discovery |
| Jun 1, 2025 | Rachel Yap Martens became VP, Partnerships & Corp Strat |
| Mar 3, 2025 | Lisa DeFrancesco listed as SVP, IR and Corp Comm (previously VP, IR and Corp Strategy) in SEC filings |
| Feb 18, 2025 | Wendy McDermott listed as SVP, Human Resources (previously VP, Human Resources) in SEC filings |
| Jan 2, 2025 | Scott M Coiante became SVP, Chief Financial Officer |
| Dec 5, 2024 | Artal Participations S.a r.l. became a director |
| Dec 5, 2024 | Artal Participations S.a r.l. became a 10% owner |
| Dec 2, 2024 | Ivan Cheung became a director |
| Nov 19, 2024 | The company announced the departure of Robert J Md Lefkowitz from the board in an SEC filing |
| Oct 2, 2024 | Lisa DeFrancesco became VP, IR and Corp Strategy |
| Aug 12, 2024 | Brian Corrigan became SVP, Regulatory & QA |
| Jul 25, 2024 | Siren, L.L.C. became a director |
| Jul 25, 2024 | Siren, L.L.C. became a 10% owner |
| Jul 25, 2024 | Invus Global Management, LLC became a director |
| Jul 25, 2024 | Invus Global Management, LLC became a 10% owner |
| Jul 8, 2024 | Michael Exton became a director |
| Jul 8, 2024 | Michael Exton became Chief Executive Officer |
| Apr 24, 2024 | The company announced the departure of Lonnel Coats from the board in an SEC filing |
| Apr 24, 2024 | The company announced the departure of Lonnel Coats as Chief Executive Officer in an SEC filing |
| Oct 9, 2023 | Thomas Garner became SVP, Chief Commercial Officer |
| Oct 9, 2023 | The company announced the departure of Alan S Nies from the board in an SEC filing |
| Jul 27, 2023 | Diane E. Sullivan became a director |
| Jul 18, 2023 | The company announced the departure of Frank Palantoni from the board in an SEC filing |
| Apr 28, 2023 | Raymond Debbane no longer listed as a 10% owner in SEC filings |
| Aug 1, 2022 | Raymond Debbane first listed as a 10% owner in an SEC filing |
| Feb 14, 2022 | Lonnel Coats listed as Chief Executive Officer (previously President and CEO) in SEC filings |
| Feb 14, 2022 | Brian T Crum listed as SVP, General Counsel & Secr. (previously VP, General Counsel & Secr.) in SEC filings |
| Feb 11, 2022 | Jeffrey L Wade listed as President and CFO (previously EVP, Corp Adm Affairs and CFO) in SEC filings |
| Jan 3, 2022 | Wendy McDermott became VP, Human Resources |
| Oct 28, 2021 | Kiernan Seth became VP, Chief Commercial Officer |
| Oct 1, 2021 | Kenneth B. Kassler-Taub became SVP, Regulatory & QA |
| Sep 25, 2021 | Kristen Alexander became VP, Finance and Accounting |
| Aug 2, 2021 | Craig B Granowitz became SVP, Chief Medical Officer |
| Feb 16, 2021 | Alan J Main listed as EVP, Innov & Chem Sciences (previously EVP, Commercial Supply Ops) in SEC filings |
| Jan 11, 2021 | Amaury Wittouck became a director |
| Jan 11, 2021 | Amaury Wittouck became a 10% owner |
| Jan 5, 2021 | C.V. Invus reported in an SEC filing no longer being a director |
| Jan 5, 2021 | C.V. Invus reported in an SEC filing no longer being a 10% owner |
| Dec 31, 2020 | Invus US Partners LLC became a director |
| Dec 31, 2020 | Invus US Partners LLC became a 10% owner |
| Dec 17, 2020 | Artal Treasury Ltd first on file as a director |
| Dec 17, 2020 | Artal Treasury Ltd first on file as a 10% owner |
| Oct 28, 2019 | Brian T Crum became VP, General Counsel & Secr. |
| Feb 12, 2018 | Alan J Main listed as EVP, Commercial Supply Ops (previously EVP, CMC and Supply Operations) in SEC filings |
| Nov 17, 2016 | Alexander A Santini became EVP and CCO |
Not reported recently (19)
- Alan J Main · Last reported as EVP, Innov & Chem Sciences in an SEC filing dated Mar 3, 2025
- Kristen Alexander · Last reported as VP, Finance and Accounting in an SEC filing dated Mar 3, 2025
- Brian Corrigan · Last reported as SVP, Regulatory & QA in an SEC filing dated Feb 18, 2025
- Jeffrey L Wade · Last reported as President and CFO in an SEC filing dated Jul 8, 2024
- Invus Public Equities Advisors, LLC · Last reported as a 10% owner in an SEC filing dated May 14, 2024
- Invus Public Equities, L.P. · Last reported as a 10% owner in an SEC filing dated May 14, 2024
- Invus Advisors, L.L.C. · Last reported as a 10% owner in an SEC filing dated May 14, 2024
- Invus, L.P. · Last reported as a 10% owner in an SEC filing dated May 14, 2024
- Kenneth B. Kassler-Taub · Last reported as SVP, Regulatory & QA in an SEC filing dated Feb 29, 2024
- Thomas Garner · Last reported as SVP, Chief Commercial Officer in an SEC filing dated Feb 12, 2024
- Kiernan Seth · Last reported as VP, Chief Commercial Officer in an SEC filing dated Mar 1, 2023
- Ulys, L.L.C. · Last reported as a 10% owner in an SEC filing dated Aug 9, 2022
- Invus US Partners LLC · Last reported as a director in an SEC filing dated Aug 9, 2022
- James F Tessmer · Last reported as VP, Finance & Accounting in an SEC filing dated Mar 16, 2021
- Praveen Tyle · Last reported as EVP, R&D in an SEC filing dated Mar 2, 2021
- Pascal Minne · Last reported as a director in an SEC filing dated Dec 17, 2020
- Artal Treasury Ltd · Last reported as a director in an SEC filing dated Dec 17, 2020
- Pablo Lapuerta · Last reported as EVP and CMO in an SEC filing dated Apr 24, 2020
- Alexander A Santini · Last reported as EVP and CCO in an SEC filing dated Apr 24, 2020
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
LXRX Proposed Insider Sales (Form 144)
Latest: 2024-08-15
? Form 144 Guide
Last 30d:
0 filings
· Last 90d:
0 filings
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2024-08-15 | COATS LONNEL | Former Affiliate | 300,000 | $480.0K | 2024-08-15 | Charles Schwab & Co., Inc. | — | EDGAR |
| 2023-07-12 | Seth Kiernan | Former Affiliate | 19,000 | $43.9K | 2023-07-12 | Charles Schwab & Co., Inc. | — | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-11-05
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
ETF Holders
30 ETFs hold LXRX
25 shown · $46.91M total exposure · 0.02% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.00% | $13.3M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.01% | $10.5M | $76.6B | 2026-11-06 |
| 3 | VXF Vanguard Extended Market ETF | Vanguard | 0.00% | $4.6M | — | 2026-09-30 |
| 4 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.03% | $3.8M | $13.7B | 2026-11-06 |
| 5 | XPH State Street® SPDR® S&P® Pharmaceuticals ETF | SPDR (State Street) | 0.75% | $3.5M | $466.5M | 2026-11-05 |
| 6 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.01% | $2.5M | — | 2026-09-30 |
| 7 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.01% | $2.4M | — | 2026-08-31 |
| 8 | IWC iShares Micro-Cap ETF | iShares (BlackRock) | 0.10% | $1.2M | $1.2B | 2026-11-06 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.01% | $1.2M | — | 2026-09-30 |
| 10 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.06% | $1.0M | — | 2026-11-05 |
| 11 | PRFZ Invesco RAFI US 1500 Small-Mid ETF | Nport | 0.03% | $747,193 | — | 2026-07-31 |
| 12 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.03% | $463,665 | — | 2026-09-30 |
| 13 | BBC Virtus Biotech Clinical Trials Etf | Nport | 0.81% | $373,947 | — | 2026-07-31 |
| 14 | GSSC Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF | Goldman | 0.03% | $266,622 | $1.0B | 2026-11-05 |
| 15 | SCHB Schwab U.S. Broad Market ETF | Nport | 0.00% | $250,682 | — | 2026-08-31 |
| 16 | RSSL Global X Russell 2000 ETF | Global X | 0.01% | $192,799 | — | 2026-11-06 |
| 17 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.00% | $176,203 | $4.0B | 2026-11-05 |
| 18 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.00% | $154,908 | $19.7B | 2026-11-06 |
| 19 | QQQS Invesco NASDAQ Future Gen 200 ETF | Invesco | 0.43% | $84,255 | — | 2026-11-05 |
| 20 | PILL Direxion Daily Pharmaceutical & Medical Bull 3X ETF | Direxion | 0.52% | $68,082 | — | 2026-11-06 |
| 21 | VTHR Vanguard Russell 3000 ETF | Vanguard | 0.00% | $39,197 | — | 2026-09-30 |
| 22 | MSSM Morgan Stanley Pathway Small-Mid Cap Equity ETF | Nport | 0.00% | $33,199 | — | 2026-08-31 |
| 23 | WSML iShares MSCI World Small-Cap ETF | iShares (BlackRock) | 0.01% | $32,690 | $656.6M | 2026-11-06 |
| 24 | ITWO ProShares Russell 2000 High Income ETF | ProShares | 0.01% | $22,855 | — | 2026-11-06 |
| 25 | URTY ProShares UltraPro Russell2000 | ProShares | 0.01% | $17,723 | — | 2026-11-06 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-0.14
TTM Revenue
$38.38M
TTM Net Income
$-62.35M
TTM Op. Cash Flow
$-49.23M
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q3 '26 | 2026-09-30 | $11.25M | $-14.01M | $-0.03 | $-8.08M |
| Q1 '26 | 2026-03-31 | $21.10M | $-1.04M | — | $-14.73M |
| Q4 '25 | 2025-12-31 | $5.34M | $-15.53M | $-0.04 | $-17.23M |
| Q3 '25 | 2025-09-30 | $14.18M | $-12.77M | $-0.04 | $-23.83M |
| Q2 '25 | 2025-06-30 | $28.87M | $3.25M | $0.01 | $16.99M |
| Q1 '25 | 2025-03-31 | $1.26M | $-25.30M | $-0.07 | $-43.78M |
| Q4 '24 | 2024-12-31 | $26.47M | $-33.77M | $-0.09 | $-21.49M |
| Q3 '24 | 2024-09-30 | $1.75M | $-64.81M | $-0.18 | $-53.62M |
| Q2 '24 | 2024-06-30 | $1.65M | $-53.43M | $-0.17 | $-48.54M |
| Q1 '24 | 2024-03-31 | $1.13M | $-48.40M | $-0.20 | $-55.13M |
| Q4 '23 | 2023-12-31 | $672.00K | $-49.76M | $-0.20 | $-50.55M |
| Q3 '23 | 2023-09-30 | $148.00K | $-50.52M | $-0.21 | $-41.62M |
Q3 2026 • period ending 2026-09-30 • filed 2026-11-05
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
3.41
P/S
9.95
EV/EBITDA
—
EV/Sales
10.11
ROE
-12.9%
ROA
-9.7%
Div Yield
0.00%
FCF Yield
-5.61%
Debt/Equity
0.24
Current Ratio
—
Market Cap
$691.11M
as of 2026-11-09
LXRX vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| LLY Eli Lilly & Co. | $1.21T | 46.0 | +45.5% | +31.3% | 27 |
| VTRS Viatris Inc. Common Stock | $22.8B | — | +4.3% | +64.5% | 43 |
| MANE Veradermics, Incorporated | $5.8B | — | — | +283.1% | 1 |
| XERS Xeris Biopharma Holdings, Inc. Common St | $2.8B | — | +38.4% | +114.7% | 15 |
| SEPN Septerna, Inc. Common Stock | $2.3B | — | +13520.1% | +76.9% | 36 |
| MAZE Maze Therapeutics, Inc. Common Stock | $1.9B | — | +700.0% | −12.0% | 43 |
| SUPN Supernus, Inc. Common Stock | $1.5B | — | +26.9% | −44.0% | 11 |
| PCRX Pacira BioSciences, Inc. Common Stock | $1.5B | 104.2 | +5.7% | +49.1% | 67 |
| LXRX Lexicon Pharmaceuticals, Inc. | $815M | — | −45.8% | +63.6% | 55 |
| Peer median | $2.5B | 75.1 | +38.4% | +56.8% | 32 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
26.70M
SI % of Float
11.79%
Days to Cover
12.97
Short Vol Ratio
56.4%
Free Float
226.44M
Float %
50.9%
Short interest 2026-10-15 • Short volume 2026-11-06 • Float 2026-08-14